S&P UPGRADES OPINION ON SHARES OF WEBMD HEALTH TO BUY FROM HOLD
(S&P Capital IQ)
We are raising our DCF-driven 12-month target to $18 from $16. We are lowering our '13 and '14 EPS estimates to $0.15 from $0.20 and $0.30 from $0.40. WBMD has fallen more than 60% year to date, reflecting notable challenges. However, we see more limited risk and potential positive catalysts. WBMD has a new CEO and new head of its consumer unit. It has introduced new consumer offerings and is making progress in Europe. We see profits resuming in '13, a flexible balance sheet, and possible value-added corporate transactional activity. We also view WBMD as a potential M&A target.
i was with them til the last line.too much big money bought shares in the27-35 area.dont see offers like that coming with declining earnings,doesnt make sense.i do but that we will see attempts at shareholder enhancement after the first of the year when ichan has some actual pull,the other issue is what happen on the next earnings call.the easy short money has been made as has the easy protection.i wish there was info on the impact of obama care on this co,it seems to cut a lot of ways.